Keep up-to-date with Shimmer

Shimmer wins Clinical Trial Wearable Sensor Technology Company of the Year 2020


Shimmer Research, a global leader in wearable technology, has been awarded Clinical Trial Wearable Sensor Technology Company of the Year 2020, by Corporate Live Wire’s Innovation and Excellence Awards. Shimmer was recognized for its Verisense wearable sensors platform, which is designed specifically to meet the needs of clinical trials – with its primary focus on minimum participant burden and high-quality data. This award is a great honor and recognizes all of the hard work used to develop these activity and sleep monitors that can be worn continuously for up to six months.

This Verisense product was developed to answer specific needs from the clinical research market regarding wearable technology. These include:

  • Longer battery life – Verisense offers up to 6 months continuous battery life.
  • Water and impact resistant – participants can wear them in the shower and while doing all daily activities.
  • Comfortable fit – Verisense cradle fits with most standard watch straps allowing for a comfortable fit and flexible styling for all occasions. Additionally, the sensor can be integrated into a number of different garments for specified illnesses and end use cases.
  • Minimum participant burden – trial participants can put it on and forget about it as the data upload from the wearable sensor to the base station is completely automatic. This data is then transferred to the clinical trial site through cellular data or Wi-Fi, seamlessly.

“Shimmer has been a wearable sensor leader in the academic and corporate research markets for more than 10 years, with the highest data quality being our differentiator” said Geoffrey Gill, president of Shimmer Americas. “During the past two years, we have leveraged that experience to develop highly tailored offerings for the clinical research market. We are delighted to receive this award for our wearable technology platform, it is welcome recognition for our newest development.”

If required, the Verisense platform can monitor up to seven sensors on a participant’s body, making it invaluable for studying complex musculoskeletal or neurological conditions, such as Parkinson’s disease or epilepsy.
The future of the Verisense platform includes integration of Shimmer’s industry leading wearable sensors for academic and research purposes, the Shimmer3 family. These include ECG, EMG, GSR, PPG, Bioimpedance and more, and will allow for more complete biometric and kinematic data capture.

Shimmer’s wearable technology platform has gained widespread market acceptance because they answer the needs of the clinical trial industry. They provide and provide high quality, validated data; are easy to use and set up; and are reliable. The company also ensures that its technology continues to evolve to meet changing market needs. One such example is the creation of The Open Wearables Initiative, which aims to bring together researchers, medical device companies, and pharmaceutical companies to develop a set of open source algorithms and software tools that can be used to develop industry-accepted clinical endpoints, allowing for wider adoption of clinical trial wearable technology. For more information on this, please visit the Open Wearables Initiative.